MACK Merrimack Pharmaceuticals Inc.

6
-0.01  -0%
Previous Close 6.01
Open 5.95
Price To Book 1.36
Market Cap 80056704
Shares 13,342,784
Volume 39,935
Short Ratio
Av. Daily Volume 65,733

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial termination announced November 7, 2018.
MM-121 (SHERBOC)
HER2 negative metastatic breast cancer
Phase 2 data released June 25, 2018 - endpoints not met.
MM-141 - CARRIE
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
MM-302 HERMIONE
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
ONIVYDE
Cancer - second line pancreatic
Phase 2 trial discontinued due to futility - noted October 19, 2018.
MM-121 SHERLOC
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
ONIVYDE
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
ONIVYDE
Cancer - front line pancreatic
Announced April 4, 2019 discontinuation of development.
MM-310
Solid tumors
Poster at ASCO June 2018.
MM-121
Solid tumors

Latest News

  1. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
  2. Merrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation
  3. The Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather Upset
  4. The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership
  5. Merrimack shelves another cancer drug, plans more layoffs
  6. Merrimack Discontinues Development of MM-310
  7. Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
  8. Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results
  9. New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
  10. Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?
  11. Edited Transcript of MACK earnings conference call or presentation 7-Nov-18 1:30pm GMT
  12. John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman
  13. Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3
  14. Research Report Identifies Merrimack Pharmaceuticals, PNM Resources, Inc. (Holding Co.), Carrols Restaurant Group, American Axle & Manufacturing, CBIZ, and Nova Measuring Instruments with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  15. Merrimack to shelve lead cancer drug, lay off most of workforce
  16. Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review